Tdspharm Co., Ltd. (KOSDAQ:464280)
5,310.00
-200.00 (-3.63%)
Jul 21, 2026, 3:10 PM KST
Tdspharm Revenue
Tdspharm had revenue of 8.07B KRW in the quarter ending March 31, 2026, with 52.87% growth. This brings the company's revenue in the last twelve months to 30.41B, up 19.57% year-over-year. In the year 2025, Tdspharm had annual revenue of 27.62B with 0.37% growth.
Revenue (ttm)
30.41B
Revenue Growth
+19.57%
P/S Ratio
1.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
30.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.62B | 102.10M | 0.37% |
| Dec 31, 2024 | 27.52B | -2.53B | -8.42% |
| Dec 31, 2023 | 30.05B | 4.46B | 17.43% |
| Dec 31, 2022 | 25.59B | 5.77B | 29.11% |
| Dec 31, 2021 | 19.82B | 1.80B | 9.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| ALTEOGEN | 203.76B |
| BCWORLD PHARM. | 79.81B |
| Aprogen Biologics | 78.00B |
| HASS Corp. | 16.58B |
| LAMEDITECH | 6.08B |